Sep 21 2026 11:37 PM EST
Argenx to Acquire Forte Biosciences for $2.2 B After Positive Vitiligo Data
Forte Biosciences (NASDAQ: FBRX) announced a definitive cash‑offer from Argenx at $77 per share, valuing the company at roughly $2.2 billion. The proposal, disclosed on July 27 2026, came on the heels of statistically significant Phase 1b vitiligo data released on July 9, and propelled the stock from $20.92 on July 2 to $76.56 on August 4 – a gain of about 266% in less than five weeks.
The July 9 topline results showed a mean F‑VASI improvement of 29.6% versus 7.9% for placebo (p=0.020), with the severe‑baseline cohort achieving 43.2% improvement (p=0.006). The data, combined with a Fast Track designation for FB102 in celiac disease granted in May 2026, set the stage for the premium offer.
Acquisition announcement drives price surge
Argenx’s offer represents an 86% premium to the volume‑weighted average price of Forte shares since the July 9 data release. The cash‑only structure, financed entirely from Argenx’s balance sheet, eliminates financing risk and signaled strong confidence in FB102’s commercial potential. The market reaction – a roughly 40% jump in Forte’s share price on July 27 – reflected investors’ reassessment of the company’s valuation, moving from a pre‑revenue, loss‑making biotech to a strategic asset within Argenx’s immunology platform.
Clinical milestones underpin the deal
FB102 is being pursued in three immune‑mediated indications. The vitiligo Phase 1b read‑out provided the first proof‑of‑concept, while the celiac disease program, the most advanced, carries a Fast Track designation and is slated for Phase 2 topline data in the second half of 2026. A Phase 1b alopecia areata read‑out is also expected later in 2026. These upcoming data points are now viewed as the primary post‑acquisition catalysts, shaping Argenx’s integration plan.
Financial position and cash runway
Forte reported cash and cash equivalents of $58.2 million at the end of March 2026, which rose to $198.5 million by June 30 2026 after a $172.5 million equity raise in April. The company’s Q2 FY2026 earnings per share of ‑$0.97 beat consensus of ‑$1.00, reflecting a 21.8% quarterly improvement. Net loss narrowed to $23.3 million for the quarter, a 5.4% YoY reduction, while R&D expense surged to $22.2 million, underscoring the heavy investment in clinical programs.
Sector context and investor sentiment
The biotech sector has benefited from a relatively stable regulatory environment and continued investor appetite for catalyst‑driven, pre‑revenue companies. Forte’s inclusion in the Russell 2000 Dynamic Index in late June 2026 broadened its visibility among index‑aware investors. Analyst coverage shifted from strong‑buy to hold or sell in late July, with an average price target of $71.67, implying modest downside from the current price of $76.99. Institutional ownership stands at 77.6%, reflecting confidence among large investors despite the company’s negative earnings.
Risks and unanswered questions
Key risks include the timing and outcome of the Phase 2 celiac disease read‑out and the Phase 1b alopecia areata data, both slated for the second half of 2026. Failure to meet clinical endpoints could erode the acquisition premium and leave Argenx with a non‑commercial asset. Additionally, Forte remains a loss‑making entity with a burn rate exceeding $20 million per quarter; any delay in funding or unexpected cash‑flow pressure could strain the runway. Integration risk, antitrust clearance under the Hart‑Scott‑Rodino waiting period, and the broader market’s tolerance for high‑valuation, pre‑revenue biotech stocks also remain material uncertainties.